Please assess the completion status of the following clinical trial:

Trial Title: MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-75 years old with newly diagnosed histologically proven resected melanoma~2. Stage: IIa (T2b, T3a), IIb (T3b T4a) and IIc (T4b), N0, M0~3. Signed informed Consent~4. Willingness to provide blood samples~5. Performance Status of 0-1~6. Hematopoietic functionality at the entry of the study: leukocytes, platelets, haemoglobin and neutrophiles within the normal limits of laboratory references~7. Hepatic and renal functionality at the entry of the study within the normal range of each laboratory~8. Serum and urinary calcium within the upper limit of laboratory references.~Exclusion Criteria:~1. Primary not cutaneous melanoma~2. Clinical/radiological evidence or laboratory/pathology report of not completely resected melanoma~3. History of cancer (other than Carcinoma in situ (CIN) and non melanoma skin cancere (NMSC)~4. Current daily use of at least 600 IU/day of supplemental vitamin D or calcitriol or high dose of calcium therapy (e.g. calcium citrate with vitamin D) within the prior 6 months greater than 600 mg calcium per day during study~5. History of recurrent renal calculi or hypercalcemia (\>10mg/dl), current and chronic use of oral corticosteroids~6. History of malabsorption syndrome (e.g., pancreatic insufficiency, celiac disease, Crohn disease or tropical sprue)~7. History of small intestinal resection (e.g., ileal bypass surgery for treatment of morbid obesity resection \> 50 % of slim bowel)~8. Hypersensitivity to cholecalciferol or one of its components~9. Chronic liver disease, chronic renal disease, or renal dialysis~10. History of parathyroid disease and sarcoidosis~11. Pregnancy or breast feeding or planning on becoming pregnant during the 3 years of treatment~12. Chronic alcoholism~13. Any medical condition that in the physician's opinion would potentially interfere with vitamin D absorption, such as celiac sprue, ulcerative colitis, patients treated pharmacologically for obesity~14. Any logistic condition that do not allow follow-up of the disease of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): Vitamin D3 administration
- placebo (Type: PLACEBO_COMPARATOR): matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).